NYSE - Delayed Quote USD

Elanco Animal Health Incorporated (ELAN)

17.19 +0.21 (+1.24%)
At close: May 17 at 4:00 PM EDT
Loading Chart for ELAN
DELL
  • Previous Close 16.98
  • Open 17.00
  • Bid --
  • Ask 27.50 x 2900
  • Day's Range 16.85 - 17.42
  • 52 Week Range 7.88 - 17.43
  • Volume 5,540,367
  • Avg. Volume 4,412,938
  • Market Cap (intraday) 8.495B
  • Beta (5Y Monthly) 1.34
  • PE Ratio (TTM) --
  • EPS (TTM) -2.65
  • Earnings Date Aug 5, 2024 - Aug 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 19.53

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

www.elanco.com

9,300

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ELAN

Performance Overview: ELAN

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ELAN
15.37%
S&P 500
11.18%

1-Year Return

ELAN
101.29%
S&P 500
29.04%

3-Year Return

ELAN
50.60%
S&P 500
27.06%

5-Year Return

ELAN
47.91%
S&P 500
84.38%

Compare To: ELAN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ELAN

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    8.49B

  • Enterprise Value

    13.91B

  • Trailing P/E

    --

  • Forward P/E

    18.08

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.94

  • Price/Book (mrq)

    1.40

  • Enterprise Value/Revenue

    3.19

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -29.83%

  • Return on Assets (ttm)

    1.03%

  • Return on Equity (ttm)

    -19.24%

  • Revenue (ttm)

    4.37B

  • Net Income Avi to Common (ttm)

    -1.3B

  • Diluted EPS (ttm)

    -2.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    345M

  • Total Debt/Equity (mrq)

    95.20%

  • Levered Free Cash Flow (ttm)

    84.75M

Research Analysis: ELAN

Company Insights: ELAN

Research Reports: ELAN

People Also Watch